Chief Medical Officer
Scilex Holding Company
Palo Alto, California
Dr Dmitri Lissin currently serves as Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs of Scilex Holding Company (Scilex and Semnur Pharmaceuticals). Prior to his current position Dmitri was clinical development executive at Xenoport and DURECT Corporation, responsible for conduct of multiple clinical research programs in pain management and neurology. Dr. Lissin has a broad expertise with proprietary drug-delivery technologies applied to therapeutic products. Most of his experience involves clinical development of novel oral, transdermal, implantable, and injectable formulations containing existing active pharmaceutical ingredients. He received his degree at the National Medical University of Russia and post-doctoral training at the University of California San Francisco.
Disclosure information not submitted.